YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Australian shares are experiencing a period of relative stability, with investors cautiously observing market signals following the U.S. Federal Reserve's decision to hold rates steady and a recent unexpected inflation rise. In this contex…
As the Australian market approaches the holiday season, it seems to be slowing down with a slight dip of 0.2%, largely attributed to profit-taking before the break. Despite this lull, investors can still find intriguing opportunities in pe…
The Australian market is experiencing a cautious phase, with traders pausing to assess recent volatility and upcoming significant earnings reports. For investors willing to explore beyond well-known stocks, penny stocks—typically represent…
Australian shares have shown a positive shift following the successful meeting between Anthony Albanese and Donald Trump, which focused on critical minerals and the AUKUS partnership. As investors navigate these developments, attention tur…
The Australian market has seen a mixed performance recently, with sectors like Health Care and Materials showing resilience despite broader challenges in Utilities and Financials. In such fluctuating conditions, identifying stocks with str…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
Starpharma Holdings Limited (ASX:SPL) has rebounded strongly over the last week, with the share price soaring 42%. But only the myopic could ignore the astounding decline over three years. To wit, the share price sky-dived 88% in that time…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference serie…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big losses. Zooming in on an example, the Starpharma Holdings Limited (ASX:SPL) share price dropped 68% in the last half decade. W…
Key Insights Significantly high institutional ownership implies Starpharma Holdings' stock price is sensitive to their trading actions 50% of the business is held by the top 8 shareholders Using data from company's past performance alongsi…
Melbourne, Victoria --News Direct-- Starpharma Holdings Limited Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) CEO Dr Jackie Fairley speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is focused o…
Starpharma Holdings (ASX:SPL) First Half 2023 Results Key Financial Results Revenue: AU$1.71m (down 16% from 1H 2022). Net loss: AU$8.28m (loss narrowed by 2.0% from 1H 2022). AU$0.02 loss per share (improved from AU$0.021 loss in 1H 2022)…
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high. Zooming in on an example, the Starpharma Holdings Limited (ASX:SPL) share price dropped 60% in the last half decade. We certa…
Shareholders of Starpharma Holdings Limited (ASX:SPL) will have been dismayed by the negative share price return over the last three years. Per share earnings growth is also poor, despite revenues growing. In light of this performance, sha…
MELBOURNE, Australia, Oct. 25, 2022 /PRNewswire/ -- An antiviral barrier nasal spray called VIRALEZE™ will launch in Hong Kong and Macau in the coming weeks, following a recent sales and distribution agreement between the product's develop…
To get a sense of who is truly in control of Starpharma Holdings Limited (ASX:SPL), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 53% owne…
Virtual Investor Conferences NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Inv…
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new DEP®…
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Starpharma Holdings Limited's (ASX:SPL) case, it's fantastic news for shareholders. Although we don't think shareho…
MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE™ nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model. VIR…
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of Starpharma Holdings Limited (ASX:SPL) have suffered share price declines over the last year. To wit the share price is down…
The big shareholder groups in Starpharma Holdings Limited (ASX:SPL) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that…
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we think about how risky a company is, we alwa…
The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 SPL7013 showed potent antiviral ac…
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Starpharma Holdings Limited's (ASX:SPL) instance, it's good news for shareholders. While we would never sugges…
Starpharma Holdings Limited (ASX:SPL) shareholders have seen the share price descend 13% over the month. But the silver lining is the stock is up over five years. However we are not very impressed because the share price is only up 38%, le…
Starpharma has signed a 5-year supply and distribution agreement for VIRALEZE™ in Vietnam The agreement includes a minimum commitment of 1 million units in the first year VIRALEZE™ is scheduled to be officially launched in Vietnam today, f…
MELBOURNE, Australia, Dec. 1, 2021 /PRNewswire/ -- Australian biotech company Starpharma today announced that its broad spectrum antiviral nasal spray, VIRALEZE™, has been registered for sale in Vietnam, with the product scheduled to launc…
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while h…
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease. DEP® cabazitaxel is a pate…
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. The company showed that 100…
A look at the shareholders of Starpharma Holdings Limited (ASX:SPL) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Compan…
MELBOURNE, Australia, Oct. 8, 2021 /PRNewswire/ -- Australian biotech company Starpharma today announced it has signed a sales and distribution agreement for its VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leadin…